Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 18.6% in April
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 18.6% in April
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Rating) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 32,500 shares, an increase of 18.6% from the March 31st total of 27,400 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 15,400 shares, the short-interest ratio is currently 2.1 days.
Armata製藥公司(紐約證券交易所代碼:ARMP-GET Rating)是4月份空頭股數大幅增長的接受者。截至4月15日,空頭股數共有3.25萬股,比3月31日的2.74萬股增加了18.6%。目前,該公司0.3%的股份被賣空。以日均成交量15,400股計算,目前短息比為2.1天。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a report on Friday, March 17th.
另外,HC Wainwright在3月17日(星期五)的一份報告中重申了“買入”評級,並對Armata製藥公司的股票發佈了7.00美元的目標價。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. HRT Financial LP purchased a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $52,000. Jane Street Group LLC purchased a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $25,000. Northern Trust Corp purchased a new position in shares of Armata Pharmaceuticals during the first quarter valued at approximately $95,000. Vanguard Group Inc. boosted its position in shares of Armata Pharmaceuticals by 5.2% during the third quarter. Vanguard Group Inc. now owns 287,350 shares of the company's stock valued at $1,213,000 after buying an additional 14,200 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Armata Pharmaceuticals by 5.6% during the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company's stock valued at $91,000 after buying an additional 3,900 shares during the period. Hedge funds and other institutional investors own 3.76% of the company's stock.
機構投資者和對沖基金最近增持或減持了該股。HRT Financial LP在第四季度購買了Armata製藥公司新的股票頭寸,價值約5.2萬美元。建恩街集團在第四季度購買了Armata製藥公司新的股票頭寸,價值約2.5萬美元。北方信託公司在第一季度購買了Armata製藥公司的新頭寸,價值約9.5萬美元。先鋒集團(Vanguard Group Inc.)在第三季度將其在Armata PharmPharmticals的股票頭寸增加了5.2%。先鋒集團目前持有287,350股該公司股票,價值1,213,000美元,在此期間又購買了14,200股。最後,復興科技有限責任公司在第四季度將其在Armata製藥公司的股票頭寸提高了5.6%。復興科技有限責任公司現在擁有73,696股該公司的股票,價值91,000美元,在此期間又購買了3,900股。對沖基金和其他機構投資者持有該公司3.76%的股份。
Armata Pharmaceuticals Stock Down 0.1 %
Armata製藥類股下跌0.1%
Shares of Armata Pharmaceuticals stock traded down $0.00 during trading on Monday, reaching $1.62. 728 shares of the stock traded hands, compared to its average volume of 15,264. The firm has a market cap of $58.52 million, a price-to-earnings ratio of -1.43 and a beta of 1.17. Armata Pharmaceuticals has a 52-week low of $0.83 and a 52-week high of $4.92.
在週一的交易中,Armata PharmPharmticals的股價下跌了0.00美元,達到1.62美元。該股有728股易手,而其平均成交量為15,264股。該公司的市值為5852萬美元,本益比為-1.43倍,貝塔係數為1.17。Armata PharmPharmticals的52周低點為0.83美元,52周高點為4.92美元。
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Rating) last issued its quarterly earnings data on Thursday, March 16th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). The firm had revenue of $1.05 million for the quarter, compared to analysts' expectations of $1.34 million. Armata Pharmaceuticals had a negative net margin of 670.26% and a negative return on equity of 75.16%. On average, equities analysts expect that Armata Pharmaceuticals will post -1.31 EPS for the current fiscal year.
Armata製藥公司(NYSEAMERICAN:ARMP-GET Rating)最近一次發佈季度收益數據是在3月16日星期四。該公司公佈本季度每股收益為0.29美元,低於分析師普遍預期的0.25美元和0.04美元。該公司當季營收為105萬美元,高於分析師預期的134萬美元。阿瑪塔製藥公司的淨利潤率為負670.26%,淨資產回報率為負75.16%。股票分析師平均預計,Armata PharmPharmticals本財年的每股收益將為1.31美元。
Armata Pharmaceuticals Company Profile
Armata製藥公司簡介
(Get Rating)
(獲取評級)
Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Armata製藥公司是一家臨床階段的生物技術公司,專注於開發用於治療抗藥性細菌感染的噬菌體療法。該公司成立於2019年5月9日,總部位於加利福尼亞州洛杉磯。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on Armata Pharmaceuticals (ARMP)
- Insiders Drive Volatility For Keurig Dr Pepper
- After a 40% Drop, Analysts Remain Bullish on Impinj
- Visa Charges Higher After Better-Than-Expected Q2 Report
- onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
- Can Teladoc Stock Be Resuscitated?
- 免費獲取StockNews.com關於Armata製藥的研究報告(ARMP)
- 內部人士推動Keurig Dr Pepper的波動
- 在下跌40%之後,分析師仍看好Impinj
- 第二季度報告好於預期後簽證費用上漲
- On Semi晶片類股觸底,創新高
- Teladoc股票可以復甦嗎?
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Armata製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Armata製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。